Kaka85
2021-03-19
Tilray easily
Better Pot Stock: Sundial Growers or Tilray?<blockquote>更好的大麻股票：Sundial Growers还是Tilray？</blockquote>
免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。
分享至
微信
复制链接
精彩评论
我们需要你的真知灼见来填补这片空白
打开APP，发表看法
APP内打开
发表看法
2
2
{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":350951645,"tweetId":"350951645","gmtCreate":1616153282687,"gmtModify":1634526979629,"author":{"id":3567602190294873,"idStr":"3567602190294873","authorId":3567602190294873,"authorIdStr":"3567602190294873","name":"Kaka85","avatar":"https://static.tigerbbs.com/910cbde97dcc78d3d6264dbe2422fdad","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":12,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":7,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>Tilray easily</p></body></html>","htmlText":"<html><head></head><body><p>Tilray easily</p></body></html>","text":"Tilray easily","highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":2,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/350951645","repostId":1138846673,"repostType":4,"repost":{"id":"1138846673","kind":"news","pubTimestamp":1616152403,"share":"https://www.laohu8.com/m/news/1138846673?lang=zh_CN&edition=full","pubTime":"2021-03-19 19:13","market":"us","language":"en","title":"Better Pot Stock: Sundial Growers or Tilray?<blockquote>更好的大麻股票：Sundial Growers还是Tilray？</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1138846673","media":"Motley Fool","summary":"Here's how these two hot marijuana stocks compare.No cannabis stocks have attracted more attention i","content":"<p>Here's how these two hot marijuana stocks compare.No cannabis stocks have attracted more attention in 2021 so far than<b>Sundial Growers</b>(NASDAQ:SNDL)and<b>Tilray</b>(NASDAQ:TLRY). That attention has been overwhelmingly positive, considering that the share prices for both companies have almost tripled year to date.</p><p><blockquote>以下是这两只热门大麻股票的比较。到目前为止，2021年没有哪只大麻股票比<b>日晷种植者</b>（纳斯达克：SNDL）及<b>蒂尔雷</b>（纳斯达克：TLRY）。考虑到今年迄今为止两家公司的股价几乎上涨了两倍，这种关注绝大多数是积极的。</blockquote></p><p>However, the excitement of being in the limelight can fade quickly. Which of these two pot stocks is the better pick going forward? Here's how Sundial and Tilray stack up against each other.</p><p><blockquote>然而，出风头的兴奋感会很快消退。这两只大麻股中哪一只是未来更好的选择？以下是Sundial和Tilray的对比。</blockquote></p><p><b>Growth</b></p><p><blockquote><b>增长</b></blockquote></p><p>Tilray's revenuejumped 20.5% year over year in the fourth quarterto $56.6 million. The company's international medical cannabis sales skyrocketed 191%, while its Canadian adult-use recreational marijuana sales soared 49%. The only fly in the ointment for Tilray was its hemp segment, which experienced an 18% revenue decline.</p><p><blockquote>Tilray第四季度收入同比增长20.5%至5660万美元。该公司的国际医用大麻销售额猛增191%，而加拿大成人休闲大麻销售额猛增49%。Tilray唯一美中不足的是其大麻部门，收入下降了18%。</blockquote></p><p>Sundial announced its Q4 results on Wednesday, and its story wasn't nearly as good as Tilray's. The company reported net cannabis revenue of 13.9 million in Canadian dollars. While this reflected an 8% increase from the prior quarter, Sundial's revenue was down more than 5% year over year.</p><p><blockquote>Sundial周三公布了第四季度业绩，其业绩远不如Tilray。该公司报告大麻净收入为1390万加元。虽然这比上一季度增长了8%，但Sundial的收入同比下降了5%以上。</blockquote></p><p>Both Sundial and Tilray have opportunities to grow in the Canadian market, especially as the country's Cannabis 2.0 derivatives market continues to pick up momentum. However, Tilray definitely will have an advantage.</p><p><blockquote>Sundial和Tilray都有机会在加拿大市场发展，特别是随着该国大麻2.0衍生品市场继续增长。然而，Tilray肯定会有优势。</blockquote></p><p>Tilray's merger with<b>Aphria</b>(NASDAQ:APHA)is expected to close in the second quarter of 2021. The combined company will rank as the biggest global cannabis producer based on revenue. It will also claim the leading market share in the Canadian retail marijuana market.</p><p><blockquote>Tilray与<b>Aphria</b>（纳斯达克：APHA）预计将于2021年第二季度关闭。按收入计算，合并后的公司将成为全球最大的大麻生产商。它还将占据加拿大零售大麻市场的领先市场份额。</blockquote></p><p>The \"new\" Tilray will also be a top player in European medical cannabis markets because Aphria owns a major German cannabis wholesaler. Tilray also operates a large cannabis production facility in Portugal. Sundial doesn't have a presence in Europe at this point.</p><p><blockquote>“新”Tilray也将成为欧洲医用大麻市场的顶级参与者，因为Aphria拥有一家主要的德国大麻批发商。Tilray还在葡萄牙经营一家大型大麻生产设施。Sundial目前在欧洲还没有业务。</blockquote></p><p>Tilray and Aphria also have businesses in the U.S., while Sundial doesn't. Aphria acquired craft-beer maker Sweetwater Brewing, and Tilray owns leading hemp foods manufacturer Manitoba Harvest. The combined company thinks that these operations will give it a great launching pad should federal cannabis reform open the door to jump into the lucrative U.S. cannabis market.</p><p><blockquote>Tilray和Aphria在美国也有业务，而Sundial没有。Aphria收购了精酿啤酒制造商Sweetwater Brewing，Tilray拥有领先的大麻食品制造商Manitoba Harvest。合并后的公司认为，如果联邦大麻改革打开进入利润丰厚的美国大麻市场的大门，这些业务将为其提供一个很好的发射台。</blockquote></p><p><b>Financial position</b></p><p><blockquote><b>财务状况</b></blockquote></p><p>Sundial posted a net loss of CA$64.1 million in the fourth quarter. The company generated an adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) loss of CA$5.6 million and had CA$710 million in unrestricted cash as of March 15, 2021.</p><p><blockquote>Sundial第四季度净亏损6410万加元。截至2021年3月15日，该公司调整后的息税折旧摊销前利润(EBITDA)亏损为560万加元，无限制现金为7.1亿加元。</blockquote></p><p>Tilray is in a much stronger financial position even before the Aphria merger. While the company recorded a Q4 net loss of $3 million, it was a huge improvement from the net loss of $219.8 million in the prior-year period. Tilray also generated positive adjusted EBITDA of $2.2 million and had $189.7 million in cash as of the end of 2020.</p><p><blockquote>即使在Aphria合并之前，Tilray的财务状况也要强劲得多。虽然该公司第四季度净亏损为300万美元，但较去年同期2.198亿美元的净亏损有了巨大改善。截至2020年底，Tilray还产生了220万美元的正调整后EBITDA，并拥有1.897亿美元的现金。</blockquote></p><p>The financial situation for Tilray should improve once the Aphria merger closes. Aphria has delivered seven consecutive quarters of increasing adjusted EBITDA profitability. The combined entity expects to realize significant synergies within the two years following the finalization of the transaction.</p><p><blockquote>一旦Aphria合并完成，Tilray的财务状况应该会有所改善。Aphria已连续七个季度实现调整后EBITDA盈利能力增长。合并后的实体预计将在交易完成后的两年内实现显着的协同效应。</blockquote></p><p><b>Valuation</b></p><p><blockquote><b>估值</b></blockquote></p><p>Tilray's market cap currently stands at around $4.5 billion, while Sundial's is close to $2.4 billion. But is Tilray actually worth nearly twice as much as Sundial?</p><p><blockquote>Tilray的市值目前约为45亿美元，而Sundial的市值接近24亿美元。但Tilray的价值实际上是Sundial的近两倍吗？</blockquote></p><p>We can't use earnings-based valuation metrics to compare the two stocks. However, Sundial and Tilray appear to be close using price-to-sales (P/S) ratios. Sundial currently trades at around 24 times trailing-12-month sales, while Tilray trades at a P/S multiple of nearly 23.</p><p><blockquote>我们不能使用基于收益的估值指标来比较这两只股票。然而，从市销率(P/S)来看，Sundial和Tilray似乎很接近。Sundial目前的市盈率约为过去12个月销售额的24倍，而Tilray的市盈率接近23倍。</blockquote></p><p>However, it's important to remember that Tilray's sales continue to rise year over year while Sundial's are still declining year over year. This makes Tilray's valuation more attractive compared to Sundial.</p><p><blockquote>然而，重要的是要记住，Tilray的销售额继续逐年增长，而Sundial的销售额仍在逐年下降。这使得Tilray的估值与Sundial相比更具吸引力。</blockquote></p><p><b>Better pot stock?</b></p><p><blockquote><b>更好的锅汤？</b></blockquote></p><p>This decision isn't difficult. Tilray is growing faster than Sundial and seems to have stronger growth prospects going forward with the Aphria merger on the way. It claims a stronger financial position than Sundial and, to top things off, Tilray's valuation is slightly more attractive right now. On all counts, Tilray appears to be the better pot stock than Sundial.</p><p><blockquote>这个决定并不难。Tilray的增长速度比Sundial更快，并且随着Aphria合并的进行，似乎具有更强劲的增长前景。它声称比Sundial拥有更强大的财务状况，最重要的是，Tilray的估值目前略有吸引力。从各方面来看，Tilray似乎比Sundial更好。</blockquote></p><p>However, I don't think that either of these stocks is a great choice for investors. There are several other stocks that are in a better position to profit from the U.S. cannabis market growth that are more attractively valued than either Sundial Growers or Tilray.</p><p><blockquote>然而，我认为这两只股票对于投资者来说都不是一个很好的选择。还有其他几只股票能够更好地从美国大麻市场的增长中获利，它们的估值比Sundial Growers或Tilray更具吸引力。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Better Pot Stock: Sundial Growers or Tilray?<blockquote>更好的大麻股票：Sundial Growers还是Tilray？</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBetter Pot Stock: Sundial Growers or Tilray?<blockquote>更好的大麻股票：Sundial Growers还是Tilray？</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Motley Fool</strong><span class=\"h-time small\">2021-03-19 19:13</span>\n</p>\n</h4>\n</header>\n<article>\n<p>Here's how these two hot marijuana stocks compare.No cannabis stocks have attracted more attention in 2021 so far than<b>Sundial Growers</b>(NASDAQ:SNDL)and<b>Tilray</b>(NASDAQ:TLRY). That attention has been overwhelmingly positive, considering that the share prices for both companies have almost tripled year to date.</p><p><blockquote>以下是这两只热门大麻股票的比较。到目前为止，2021年没有哪只大麻股票比<b>日晷种植者</b>（纳斯达克：SNDL）及<b>蒂尔雷</b>（纳斯达克：TLRY）。考虑到今年迄今为止两家公司的股价几乎上涨了两倍，这种关注绝大多数是积极的。</blockquote></p><p>However, the excitement of being in the limelight can fade quickly. Which of these two pot stocks is the better pick going forward? Here's how Sundial and Tilray stack up against each other.</p><p><blockquote>然而，出风头的兴奋感会很快消退。这两只大麻股中哪一只是未来更好的选择？以下是Sundial和Tilray的对比。</blockquote></p><p><b>Growth</b></p><p><blockquote><b>增长</b></blockquote></p><p>Tilray's revenuejumped 20.5% year over year in the fourth quarterto $56.6 million. The company's international medical cannabis sales skyrocketed 191%, while its Canadian adult-use recreational marijuana sales soared 49%. The only fly in the ointment for Tilray was its hemp segment, which experienced an 18% revenue decline.</p><p><blockquote>Tilray第四季度收入同比增长20.5%至5660万美元。该公司的国际医用大麻销售额猛增191%，而加拿大成人休闲大麻销售额猛增49%。Tilray唯一美中不足的是其大麻部门，收入下降了18%。</blockquote></p><p>Sundial announced its Q4 results on Wednesday, and its story wasn't nearly as good as Tilray's. The company reported net cannabis revenue of 13.9 million in Canadian dollars. While this reflected an 8% increase from the prior quarter, Sundial's revenue was down more than 5% year over year.</p><p><blockquote>Sundial周三公布了第四季度业绩，其业绩远不如Tilray。该公司报告大麻净收入为1390万加元。虽然这比上一季度增长了8%，但Sundial的收入同比下降了5%以上。</blockquote></p><p>Both Sundial and Tilray have opportunities to grow in the Canadian market, especially as the country's Cannabis 2.0 derivatives market continues to pick up momentum. However, Tilray definitely will have an advantage.</p><p><blockquote>Sundial和Tilray都有机会在加拿大市场发展，特别是随着该国大麻2.0衍生品市场继续增长。然而，Tilray肯定会有优势。</blockquote></p><p>Tilray's merger with<b>Aphria</b>(NASDAQ:APHA)is expected to close in the second quarter of 2021. The combined company will rank as the biggest global cannabis producer based on revenue. It will also claim the leading market share in the Canadian retail marijuana market.</p><p><blockquote>Tilray与<b>Aphria</b>（纳斯达克：APHA）预计将于2021年第二季度关闭。按收入计算，合并后的公司将成为全球最大的大麻生产商。它还将占据加拿大零售大麻市场的领先市场份额。</blockquote></p><p>The \"new\" Tilray will also be a top player in European medical cannabis markets because Aphria owns a major German cannabis wholesaler. Tilray also operates a large cannabis production facility in Portugal. Sundial doesn't have a presence in Europe at this point.</p><p><blockquote>“新”Tilray也将成为欧洲医用大麻市场的顶级参与者，因为Aphria拥有一家主要的德国大麻批发商。Tilray还在葡萄牙经营一家大型大麻生产设施。Sundial目前在欧洲还没有业务。</blockquote></p><p>Tilray and Aphria also have businesses in the U.S., while Sundial doesn't. Aphria acquired craft-beer maker Sweetwater Brewing, and Tilray owns leading hemp foods manufacturer Manitoba Harvest. The combined company thinks that these operations will give it a great launching pad should federal cannabis reform open the door to jump into the lucrative U.S. cannabis market.</p><p><blockquote>Tilray和Aphria在美国也有业务，而Sundial没有。Aphria收购了精酿啤酒制造商Sweetwater Brewing，Tilray拥有领先的大麻食品制造商Manitoba Harvest。合并后的公司认为，如果联邦大麻改革打开进入利润丰厚的美国大麻市场的大门，这些业务将为其提供一个很好的发射台。</blockquote></p><p><b>Financial position</b></p><p><blockquote><b>财务状况</b></blockquote></p><p>Sundial posted a net loss of CA$64.1 million in the fourth quarter. The company generated an adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) loss of CA$5.6 million and had CA$710 million in unrestricted cash as of March 15, 2021.</p><p><blockquote>Sundial第四季度净亏损6410万加元。截至2021年3月15日，该公司调整后的息税折旧摊销前利润(EBITDA)亏损为560万加元，无限制现金为7.1亿加元。</blockquote></p><p>Tilray is in a much stronger financial position even before the Aphria merger. While the company recorded a Q4 net loss of $3 million, it was a huge improvement from the net loss of $219.8 million in the prior-year period. Tilray also generated positive adjusted EBITDA of $2.2 million and had $189.7 million in cash as of the end of 2020.</p><p><blockquote>即使在Aphria合并之前，Tilray的财务状况也要强劲得多。虽然该公司第四季度净亏损为300万美元，但较去年同期2.198亿美元的净亏损有了巨大改善。截至2020年底，Tilray还产生了220万美元的正调整后EBITDA，并拥有1.897亿美元的现金。</blockquote></p><p>The financial situation for Tilray should improve once the Aphria merger closes. Aphria has delivered seven consecutive quarters of increasing adjusted EBITDA profitability. The combined entity expects to realize significant synergies within the two years following the finalization of the transaction.</p><p><blockquote>一旦Aphria合并完成，Tilray的财务状况应该会有所改善。Aphria已连续七个季度实现调整后EBITDA盈利能力增长。合并后的实体预计将在交易完成后的两年内实现显着的协同效应。</blockquote></p><p><b>Valuation</b></p><p><blockquote><b>估值</b></blockquote></p><p>Tilray's market cap currently stands at around $4.5 billion, while Sundial's is close to $2.4 billion. But is Tilray actually worth nearly twice as much as Sundial?</p><p><blockquote>Tilray的市值目前约为45亿美元，而Sundial的市值接近24亿美元。但Tilray的价值实际上是Sundial的近两倍吗？</blockquote></p><p>We can't use earnings-based valuation metrics to compare the two stocks. However, Sundial and Tilray appear to be close using price-to-sales (P/S) ratios. Sundial currently trades at around 24 times trailing-12-month sales, while Tilray trades at a P/S multiple of nearly 23.</p><p><blockquote>我们不能使用基于收益的估值指标来比较这两只股票。然而，从市销率(P/S)来看，Sundial和Tilray似乎很接近。Sundial目前的市盈率约为过去12个月销售额的24倍，而Tilray的市盈率接近23倍。</blockquote></p><p>However, it's important to remember that Tilray's sales continue to rise year over year while Sundial's are still declining year over year. This makes Tilray's valuation more attractive compared to Sundial.</p><p><blockquote>然而，重要的是要记住，Tilray的销售额继续逐年增长，而Sundial的销售额仍在逐年下降。这使得Tilray的估值与Sundial相比更具吸引力。</blockquote></p><p><b>Better pot stock?</b></p><p><blockquote><b>更好的锅汤？</b></blockquote></p><p>This decision isn't difficult. Tilray is growing faster than Sundial and seems to have stronger growth prospects going forward with the Aphria merger on the way. It claims a stronger financial position than Sundial and, to top things off, Tilray's valuation is slightly more attractive right now. On all counts, Tilray appears to be the better pot stock than Sundial.</p><p><blockquote>这个决定并不难。Tilray的增长速度比Sundial更快，并且随着Aphria合并的进行，似乎具有更强劲的增长前景。它声称比Sundial拥有更强大的财务状况，最重要的是，Tilray的估值目前略有吸引力。从各方面来看，Tilray似乎比Sundial更好。</blockquote></p><p>However, I don't think that either of these stocks is a great choice for investors. There are several other stocks that are in a better position to profit from the U.S. cannabis market growth that are more attractively valued than either Sundial Growers or Tilray.</p><p><blockquote>然而，我认为这两只股票对于投资者来说都不是一个很好的选择。还有其他几只股票能够更好地从美国大麻市场的增长中获利，它们的估值比Sundial Growers或Tilray更具吸引力。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.fool.com/investing/2021/03/19/better-pot-stock-sundial-growers-or-tilray/\">Motley Fool</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://www.fool.com/investing/2021/03/19/better-pot-stock-sundial-growers-or-tilray/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1138846673","content_text":"Here's how these two hot marijuana stocks compare.No cannabis stocks have attracted more attention in 2021 so far thanSundial Growers(NASDAQ:SNDL)andTilray(NASDAQ:TLRY). That attention has been overwhelmingly positive, considering that the share prices for both companies have almost tripled year to date.However, the excitement of being in the limelight can fade quickly. Which of these two pot stocks is the better pick going forward? Here's how Sundial and Tilray stack up against each other.GrowthTilray's revenuejumped 20.5% year over year in the fourth quarterto $56.6 million. The company's international medical cannabis sales skyrocketed 191%, while its Canadian adult-use recreational marijuana sales soared 49%. The only fly in the ointment for Tilray was its hemp segment, which experienced an 18% revenue decline.Sundial announced its Q4 results on Wednesday, and its story wasn't nearly as good as Tilray's. The company reported net cannabis revenue of 13.9 million in Canadian dollars. While this reflected an 8% increase from the prior quarter, Sundial's revenue was down more than 5% year over year.Both Sundial and Tilray have opportunities to grow in the Canadian market, especially as the country's Cannabis 2.0 derivatives market continues to pick up momentum. However, Tilray definitely will have an advantage.Tilray's merger withAphria(NASDAQ:APHA)is expected to close in the second quarter of 2021. The combined company will rank as the biggest global cannabis producer based on revenue. It will also claim the leading market share in the Canadian retail marijuana market.The \"new\" Tilray will also be a top player in European medical cannabis markets because Aphria owns a major German cannabis wholesaler. Tilray also operates a large cannabis production facility in Portugal. Sundial doesn't have a presence in Europe at this point.Tilray and Aphria also have businesses in the U.S., while Sundial doesn't. Aphria acquired craft-beer maker Sweetwater Brewing, and Tilray owns leading hemp foods manufacturer Manitoba Harvest. The combined company thinks that these operations will give it a great launching pad should federal cannabis reform open the door to jump into the lucrative U.S. cannabis market.Financial positionSundial posted a net loss of CA$64.1 million in the fourth quarter. The company generated an adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) loss of CA$5.6 million and had CA$710 million in unrestricted cash as of March 15, 2021.Tilray is in a much stronger financial position even before the Aphria merger. While the company recorded a Q4 net loss of $3 million, it was a huge improvement from the net loss of $219.8 million in the prior-year period. Tilray also generated positive adjusted EBITDA of $2.2 million and had $189.7 million in cash as of the end of 2020.The financial situation for Tilray should improve once the Aphria merger closes. Aphria has delivered seven consecutive quarters of increasing adjusted EBITDA profitability. The combined entity expects to realize significant synergies within the two years following the finalization of the transaction.ValuationTilray's market cap currently stands at around $4.5 billion, while Sundial's is close to $2.4 billion. But is Tilray actually worth nearly twice as much as Sundial?We can't use earnings-based valuation metrics to compare the two stocks. However, Sundial and Tilray appear to be close using price-to-sales (P/S) ratios. Sundial currently trades at around 24 times trailing-12-month sales, while Tilray trades at a P/S multiple of nearly 23.However, it's important to remember that Tilray's sales continue to rise year over year while Sundial's are still declining year over year. This makes Tilray's valuation more attractive compared to Sundial.Better pot stock?This decision isn't difficult. Tilray is growing faster than Sundial and seems to have stronger growth prospects going forward with the Aphria merger on the way. It claims a stronger financial position than Sundial and, to top things off, Tilray's valuation is slightly more attractive right now. On all counts, Tilray appears to be the better pot stock than Sundial.However, I don't think that either of these stocks is a great choice for investors. There are several other stocks that are in a better position to profit from the U.S. cannabis market growth that are more attractively valued than either Sundial Growers or Tilray.","news_type":1,"symbols_score_info":{}},"isVote":1,"tweetType":1,"viewCount":770,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":["TLRY"],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":12,"xxTargetLangEnum":"ORIG"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/350951645"}
精彩评论